螺内酯对慢性心力衰竭患者血清N末端B型钠尿肽前体及心功能分级的影响

摘要

Objective To investigate the effects of spironolactone with chronic heart failure (CHF) patients with serum N-terminal B-type natriuretic peptide precursor (NT-proBNP) and cardiac function classification.Methods 50 cases of chronic heart failure in our hospital from January 2015 to June 2016 were selected, all the patients were treated with conventional treatment combined with spironolactone. The change of serum NT-proBNP level and NYHA cardiac function classification were observed before and after treatment.Results After treatment, the serum level of NT-proBNP was lower than that before treatment, the difference was statistically significant (P < 0.05); After treatment, patients with NYHA cardiac function classiifcation was (2.32±0.32), lower than before treatment (3.65±0.52) level, the difference was statistically signiifcant (P < 0.05).Conclusion Spironolactone can effectively improve heart function in patients with chronic heart failure, decreased serum NT-proBNP level, to protect the patient's treatment effect, to improve their quality of life.%目的：探讨螺内酯对慢性心力衰竭（心衰）患者血清N末端B型钠尿肽前体（NT-proBNP）及心功能分级的影响。方法选取我院2015年1月～2016年6月收治的慢性心衰患者50例，所有患者采用用常规治疗联合螺内酯治疗。观察患者治疗前后血清NT-proBNP水平及NYHA心功能分级的变化。结果治疗后，患者血清NT-proBNP水平低于治疗前，差异具有统计学意义（P＜0.05）；治疗后，患者NYHA心功能分级为（2.32±0.32）级，低于治疗前（3.65±0.52）级，差异具有统计学意义（P＜0.05）。结论螺内酯可以有效改善慢性心衰患者的心功能状态，降低血清NT-proBNP水平，保障患者的治疗效果，改善其生活质量。